Belinostat is primarily used as an anticancer agent, specifically in the treatment of peripheral T-cell lymphoma (PTCL), a rare and aggressive type of non-Hodgkin’s lymphoma. It functions as a histone deacetylase (HDAC) inhibitor, which means it helps increase the expression of certain tumor suppressor genes by allowing chromatin to remain in a more open and transcriptionally active state. This can lead to cell cycle arrest, differentiation, and apoptosis in cancer cells. It is typically administered intravenously and is often considered for patients who have relapsed or are refractory to prior treatments. Belinostat has shown clinical activity in various hematological malignancies and is also being investigated in clinical trials for solid tumors, including ovarian, lung, and liver cancers, sometimes in combination with other chemotherapeutic agents or radiation. Its ability to sensitize tumor cells to other therapies enhances its potential in multimodal cancer treatment strategies.